Mirada Medical to Showcase Innovative Oncology Imaging Software Portfolio at Los Angeles Radiological Society Midwinter Conference

OXFORD, UK and PHILADELPHIA, PA--(Marketwire - February 10, 2011) -

Mirada Medical Limited
(“Mirada” or “the Company”)

Mirada Medical to Showcase Innovative Oncology Imaging Software Portfolio at Los Angeles Radiological Society Midwinter Conference

Oxford, UK and Philadelphia, PA: Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, announced today that it will be showcasing its multi-modality imaging software for radiology and radiation oncology at the 63rd Annual Midwinter Conference of the Los Angeles Radiological Society to be held at the Pasadena Convention Center, CA on February 12th and February 13th 2011.

At the conference, Mirada will be demonstrating the unique oncology fusion workflows of its XD3 image analysis software, including new CT, MR, PET/CT and MR/PET analysis tools designed to enhance speed and accuracy across the complete spectrum of imaging tasks, from diagnosis and staging through to treatment response assessment and follow-up.

The new tools coupled with Mirada’s industry leading deformable registration technology and
built-in support for standard and user-defined response assessment protocols such as RECIST, WHO and PERCIST give the clinician exceptional power to review, compare and quantify a patient’s complete set of current and previous imaging studies.

Mirada will also showcase its products to support improved imaging and productivity in radiation therapy. Central to the presentation will be imaging workflows to support adaptive radiation therapy through the software assisted assessment of anatomical change during treatment. Mirada’s technology leading deformable image registration technologies will power applications such as contour warping from planning to re-planning CT and fusion of PET to planning CT.

Mirada’s team will be available to show how the referring physician can now have access to rich web-based fusion viewing capabilities, allowing them to view PET/CT, MR-PET and even CT-MR-PET fused images, reports and findings that the reading radiologist or nuclear medicine clinician has sent.

Mirada’s technologies are developed by world renowned scientists and dedicated engineers and the Company is focused on providing users with oncology imaging solutions to enhance their workflow while optimizing the most accurate and consistent reporting and quantitative knowledge share in the multi-modal diagnosis and treatment of cancer.

Hugh Bettesworth, CEO of Mirada Medical, said: “LARS is an important conference, and the inter disciplinary focus on both radiology and radiation oncology fits perfectly with Mirada’s philosophy of developing products which both support the highest standards of quantified image analysis and foster improved collaboration and information sharing between the specialists who work together with the patient to fight disease.”

Mirada Medical will showcase its latest and industry leading developments at the Los Angeles Radiological Society Midwinter Radiology and Radiation Oncology Conference technical exhibition, booth #21, Pasadena Conference Center, Pasadena, CA on the 12th and 13th February 2011.

About Mirada Medical

Mirada Medical Limited develops internationally recognized medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical’s technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specializes in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada’s advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient’s condition. Mirada’s products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.

Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world’s leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada’s products are sold by Mirada but also by major healthcare players such as McKesson, Varian, Toshiba, Vital Images, Sectra and Carestream.

The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information about Mirada Medical, please visit www.mirada-medical.com.

Press Release (PDF)
http://hugin.info/143183/R/1487710/423179.pdf